Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

Go back to Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Delayed: 244.32 +4.76 (1.99%)
Previous Close $239.56    52 Week High $109.10 
Open $240.37    52 Week Low $31.38 
Day High $247.10    P/E N/A 
Day Low $237.97    EPS $-1.45 
Volume 1,152,873       

GENZYME (NASDAQ: GENZ) Delayed: 38.20 +0.73 (1.95%)
Previous Close $37.47    52 Week High $76.48 
Open $37.71    52 Week Low $65.50 
Day High $38.20    P/E 318.33 
Day Low $37.71    EPS $0.12 
Volume 3,079       

BANCO SANTANDER S.A. (NYSE: SAN) Delayed: 14.62 +0.31 (2.17%)
Previous Close $14.31    52 Week High $5.58 
Open $14.59    52 Week Low $3.60 
Day High $14.64    P/E N/A 
Day Low $14.53    EPS $0.00 
Volume 11,927,946       

SANOFI (NASDAQ: SNY) Delayed: 42.50 +0.02 (0.05%)
Previous Close $42.48    52 Week High $44.76 
Open $42.64    52 Week Low $36.81 
Day High $42.78    P/E N/A 
Day Low $42.47    EPS $0.00 
Volume 2,484,466